thanks for the tip, but am not too confident with this one. The company's portfolio is quite meagre, only around $400,000 and that's being generous. But who knows if it takes off it will be in the big time. Looks like a few biotechs are on the hopefull at this point. Pity NRT is heading south rapidly. Any news on that?